Form 4: Cartesian Therapeutics Director Boosts Stake

Cartesian Therapeutics Director Timothy A. Springer acquired 2,600 common stock units and 7,800 stock options, increasing his beneficial ownership.

Summary

• Timothy A. Springer, a Director and 10% Owner of Cartesian Therapeutics, Inc. (RNAC), acquired additional securities.
• On January 2, 2026, Springer acquired 2,600 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs represent a contingent right to receive one share of common stock each and will vest in full on January 2, 2027.
• Additionally, on January 2, 2026, Springer acquired 7,800 Stock Options (Right to Buy) at a price of $0 per option, with an exercise price of $6.76 per share.
• These stock options become exercisable on January 2, 2027, and have an expiration date of January 1, 2036.
• Following these transactions, Springer directly beneficially owns 8,646,285 shares of Common Stock and 7,800 derivative securities (stock options).
• Indirect beneficial ownership includes 330,695 shares held by his wife and 656,513 shares held by TAS Partners LLC, where Springer is the managing member.

Sentiment

Score: 7

Explanation: The acquisition of additional securities by a Director and 10% Owner, even if compensation-related, generally indicates a positive alignment of interests and confidence in the company's future. This is a standard disclosure for insider transactions.

Positives

• A Director and 10% Owner increasing their stake in the company can signal confidence in its future prospects.
• The acquisition of Restricted Stock Units and Stock Options aligns the insider's interests with long-term shareholder value through future vesting and exercise.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction.

Industry Context

This insider transaction reflects an individual's investment decision and compensation structure within Cartesian Therapeutics, Inc., rather than broader industry trends. Insider buying can sometimes be interpreted as a positive signal for the company's future within its sector.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive sign of management's commitment and belief in the company's value.
• The compensation structure involving RSUs and stock options aligns the interests of the director with long-term shareholder returns.

Next Steps

• The 2,600 Restricted Stock Units are scheduled to vest on January 2, 2027.
• The 7,800 Stock Options will become exercisable on January 2, 2027, and expire on January 1, 2036.

Key Dates

Keywords

Cartesian Therapeutics, RNAC, Timothy A. Springer, Insider Transaction, Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership